Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro
about
Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionPathogenesis of human immunodeficiency virus infectionHuman immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophagesExpression of a human monoclonal anti-(rhesus D) Fab fragment in Escherichia coli with the use of bacteriophage lambda vectors.Complement Evasion Strategies of Viruses: An Overview.Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activityHIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodiesProduction of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.Bimodal AIDS vaccine approach: induction of cellular as well as humoral immunity can protect from systemic infection.Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.A novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infectionMucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge.Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine designEnhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein.Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodiesEfficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophagesCharacterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells.Mapping the epitopes of antibodies.Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodiesMolecular characterization of five human anti-human immunodeficiency virus type 1 antibody heavy chains reveals extensive somatic mutation typical of an antigen-driven immune response.Fc receptors in antibody-dependent enhancement of viral infections.Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis.Antibody mediated enhancement of HIV-1 infection of an EBV transformed B cell line is CD4 dependent.Affinity of anti-GP41 antibody in patients infected with human immunodeficiency virus type 1.
P2860
Q21245045-E0E15005-1C43-4AEE-A304-67949AB21EDBQ24634681-05022814-7537-44E0-9637-5B99979A5CF9Q24675546-91A23AC3-5663-474D-AD7A-C78B2D764DADQ24681784-B288F7D8-3104-4CFC-A008-3971857DEB48Q27486215-C9928757-C29C-4D16-9585-C4F0C8ACD464Q33321464-4F2FF159-62ED-4E3E-BE75-2CE96BA27493Q33804431-1602C57A-79EF-4960-8C76-280281D3CC78Q33807129-3ECD2C71-09C7-4863-8E56-673215477F5CQ33826951-3FE47F9E-6CF8-4FE9-AD06-BC4AB4595092Q33869882-B4295E3C-6F55-4D97-BFF8-E1021AA8DB47Q34097650-FE009113-2ACF-47AA-AD9E-77BDAE7E5B76Q34197974-CBDD6C9A-8D9F-4981-947C-3A7238531618Q34306804-7E0BD613-28DF-484D-9696-1F65D4757E1CQ34361680-3D85031A-73F0-426E-B0F1-1CADF8DC7093Q35198510-82CBF988-F25A-4AB3-9534-84C094488FADQ35867981-29934662-E157-4967-B495-7B07E7B14A24Q35876233-C58EBE25-6FC6-49DA-A382-35EBC66A31B9Q35884740-08F9A762-08A5-470A-9417-1F688A1A2E32Q36376210-404C3028-D2B1-480A-B051-4ABD52070750Q36497712-C3A7D5EF-9542-48D5-9A93-0F7A48AE55A8Q36630413-5B68034D-418D-4FBD-91E6-5E446B6BD20FQ36634439-DEF19F92-6224-46B0-B817-95857255B685Q36697927-089F2D37-84BB-4B6A-AB5E-CF83D8BF402EQ36793253-E42F2958-8484-48FF-BD0C-0C1DC56C70F7Q36797252-6C191590-DED1-4A59-9C74-320511BCC5F8Q36797335-6B9C52EB-8F33-4E9C-9655-4A098BE7AE7CQ36797706-07EDA90D-D938-4891-B6A6-FBF20B32846EQ37024671-1361AC9B-3C50-4489-8634-256845F7FA07Q37284795-1F387C8B-D3FE-4B57-996A-F1D3DDEB644EQ37587941-A3627023-5E17-414E-9ED9-35F582DA0870Q38615396-4A91F6C9-3C05-4E6A-97E3-B646C725D7A2Q40106699-05BE8413-58D7-47A8-B117-69E961E80CE2Q40397998-1648BB5D-C3B8-44B7-A449-9269BE964647Q41599750-B16BE2D2-AC1C-4A77-A473-55CEA8BA5626Q45774505-49841BB9-9E5C-4703-B7EC-5F909041BDD8
P2860
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human monoclonal antibodies to ...... hance HIV-1 infection in vitro
@en
Human monoclonal antibodies to the human immunodeficiency virus type 1
@nl
type
label
Human monoclonal antibodies to ...... hance HIV-1 infection in vitro
@en
Human monoclonal antibodies to the human immunodeficiency virus type 1
@nl
prefLabel
Human monoclonal antibodies to ...... hance HIV-1 infection in vitro
@en
Human monoclonal antibodies to the human immunodeficiency virus type 1
@nl
P2093
P2860
P921
P356
P1476
Human monoclonal antibodies to ...... hance HIV-1 infection in vitro
@en
P2093
T Kawamura
W E Robinson
W M Mitchell
Y Matsumoto
P2860
P304
P356
10.1073/PNAS.87.8.3185
P407
P577
1990-04-01T00:00:00Z